Frank is Chief Executive Officer of Pacira BioSciences and has more than 30 years of global experience in product development and commercial leadership across a wide range of therapeutic areas. He was previously Chief Executive Officer of Forma Therapeutics through its acquisition by Novo Nordisk. He also served as senior vice president, global product strategy and therapeutic area head for the immunology, ophthalmology, and infectious diseases at Genentech. At Genentech, he also served as vice president of the HER2 /Breast Cancer Franchise, which included Herceptin®, Perjeta® and Kadcyla®. As vice president of oral oncolytics, Frank held P&L responsibility for Tarceva®, Zelboraf®, Erivedge® and Xeloda®. Prior to joining Genentech, Frank spent approximately thirteen years at Novartis, Janssen and Eli Lilly in various engineering, manufacturing, sales and marketing and business development roles. He holds a BS in chemical engineering from Vanderbilt University and an MBA from the Wharton Graduate School of Business. Frank also serves as executive chairman of the board of directors of privately held Therini Bio, Inc. and is a member of the board of directors of Bolt Biotherapeutics, Inc.